{"brief_title": "Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia", "brief_summary": "The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.", "condition": ["Schizophrenia"], "intervention_type": ["Drug"], "intervention_name": ["quetiapine fumarate tablets"], "criteria": "Inclusion Criteria: - Patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures - Patient has a documented clinical diagnosis of schizophrenia - Patient's parent or legal guardian will be able to accompany the patient at each scheduled study visit Exclusion Criteria: - Patients (female) must not be pregnant or lactating - Patients with a known intolerance or lack of response to previous treatment with quetiapine - Patients who have previously participated in this study", "gender": "All", "minimum_age": "13 Years", "maximum_age": "17 Years", "healthy_volunteers": "No", "keyword": "Schizophrenia", "mesh_term": ["Schizophrenia", "Quetiapine Fumarate"], "id": "NCT00090324"}